Clinical Pharmacology-Informed Development of COVID-19 Therapeutics: Regulatory Experience.

Choi, Su-Young; Arya, Vikram; Reynolds, Kellie

Choi, Su-Young; Arya, Vikram; Reynolds, Kellie.

Choi SY; Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Arya V; Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Reynolds K; Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Clin Pharmacol Ther ; 109(4): 810-812, 2021 04.

Article in English | MEDLINE | ID: covidwho-1130477

Subject(s)

Antiviral Agents/therapeutic use; COVID-19 Drug Treatment; Pharmacology, Clinical/organization & administration; Antiviral Agents/administration & dosage; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Microbiological Techniques; Pharmacology, Clinical/standards; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pharmacology, Clinical / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Clin Pharmacol Ther Year: 2021 Document Type: Article Affiliation country: Cpt.2210

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google